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Abstract
Background: Oxytocin is released in response to a meal. Further, mRNA for oxytocin and its
receptor have been found throughout the gastrointestinal (GI) tract. The aim of this study was
therefore to examine whether oxytocin, or the receptor antagonist atosiban, influence the gastric
emptying.
Methods: Ten healthy volunteers (five men) were examined regarding gastric emptying at three
different occasions: once during oxytocin stimulation using a pharmacological dose; once during
blockage of the oxytocin receptors (which also blocks the vasopressin receptors) and thereby
inhibiting physiological doses of oxytocin; and once during saline infusion.
Gastric emptying rate (GER) was assessed and expressed as the percentage reduction in antral
cross-sectional area from 15 to 90 min after ingestion of rice pudding. The assessment was
performed by real-time ultrasonography. At the same time, the feeling of satiety was registered
using visual satiety scores.
Results: Inhibition of the binding of endogenous oxytocin by the receptor antagonist delayed the
GER by 37 % compared to saline (p = 0.037). In contrast, infusion of oxytocin in a dosage of 40
mU/min did not affect the GER (p = 0.610). Satiation scores areas in healthy subjects after receiving
atosiban or oxytocin did not show any significant differences.
Conclusion:  Oxytocin and/or vasopressin seem to be regulators of gastric emptying during
physiological conditions, since the receptor antagonist atosiban delayed the GER. However, the
actual pharmacological dose of oxytocin in this study had no effect. The effect of oxytocin and
vasopressin on GI motility has to be further evaluated.
Background
During the last years it has been suggested that oxytocin
contribute to the control of the gastrointestinal (GI)
motility. Oxytocin is secreted into the blood in response
to endogenous stimulation with a fatty meal, and exoge-
nous stimulation with cholecystokinin (CCK) [1]. Both
mRNA for oxytocin and its receptor have been found
throughout the human GI tract [2]. Oxytocin has also
been shown to accelerate gastric emptying of a meal in
healthy individuals [3], and has been used to treat pro-
longed post-vagotomy gastric atony [4]. Further, oxytocin
has been shown to stimulate colonic peristalsis [5].
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The effects observed throughout the GI tract suggest that
oxytocin plays a critical role in GI motility. The aim of this
study was to further examine the effect of oxytocin on gas-
tric emptying in healthy individuals, by examining the
gastric emptying rate (GER) during continuous infusion
of either oxytocin or the oxytocin receptor antagonist
atosiban.
Methods
The study was performed according to the Helsinki decla-
ration and approved by the Ethics Committee at Lund
University. All subjects gave written, informed consent
before the experiments.
Subjects
Ten healthy volunteers (5 women) with a mean age of 40
± 16 years (range, 25–62 years) and a body mass index of
23.3 ± 1.7 kg/m2 (range, 20.8 – 26.7 kg/m2), without
symptoms or a prior history of GI disease, abdominal sur-
gery or diabetes mellitus were studied. None of the sub-
jects were using any pharmaceutical drugs affecting gut
motility. All subjects were recruited from the population
of a southern county of Sweden. Two of the subjects were
smokers. They all underwent a basal physical examination
before inclusion in the study.
Test Meal
Each subject was given 300 g of rice pudding (Scan Ris-
grynsgröt; Scan Foods, Johanneshov, Sweden). The total
energy value for the rice pudding was 1386 kJ, provided as
10 % protein, 58 % carbohydrate, and 32 % fat. The nutri-
ent composition per 100 g rice pudding was 3 g protein,
16 g carbohydrate and 4 g fat.
Drugs
The subjects were randomly examined at three different
occasions given either infusion of saline, oxytocin or an
oxytocin receptor antagonist. One ml of Syntocinon®
(Novartis, Täby, Sweden), a synthetic analogue to oxy-
tocin, with a concentration of 5 U/ml was dissolved in
250 ml NaCl and given as an intravenous infusion at a
rate of 2 ml/min, i.e. a dose of 40 mU/min. Tractocile®
(atosiban) (Ferring, Malmö, Sweden) is an antagonist to
the oxytocin receptor. It was given as an intravenous bolus
dose of 6.75 mg atosiban in a concentration of 7.5 mg/ml,
immediately followed by a continuous intravenous infu-
sion of 5 ml atosiban in a concentration of 7.5 mg/ml dis-
solved in 250 ml NaCl and given at a rate of 2 ml/min.
This gives a dose of 300 µg atosiban/min. In a third exper-
iment, 2 ml/min of 0.9 % saline was given as an intrave-
nous infusion. The infusions continued for 90 min.
The reason for choosing this dosage of oxytocin was that
this has been shown to rise the plasma oxytocin levels
remarkable in man (from 2–3 pg/ml to around 50 pg/ml)
[6], and it is the highest dosage recommended by the drug
company. This dose has been used to treat gastric atony
[4]. Further, in an earlier study a dose-response curve was
performed, and this dosage had an equal effect compared
to 20 mU/min in regard to stimulating colonic peristalsis
[5]. The rationale for choosing the atosiban dosage was
that this is the dosage recommended for clinical use by the
drug company. Although developed as an oxytocin recep-
tor antagonist, it has similar affinity for vasopressin recep-
tors [7,8].
Ultrasonography
Ultrasonographic measurements of gastric emptying were
assessed by a standardised method previously described
[9]. The patients were examined with a 3.5-MHz abdomi-
nal transducer and an Acuson 128XP 10 system (Siemens
Medical Solutions, Mountain View, CA). Gastric emptying
was monitored indirectly by determining the longitudinal
and anteroposterior diameters of a single section of the
gastric antrum, using the abdominal aorta and the left
lobe of the liver as internal landmarks to obtain the same
standardized scanning level consistently. At each observa-
tion, 3 measurements were done with the use of the mean
values of the longitudinal (d1) and the anteroposterior
(d2) diameters to calculate the cross sectional area of the
gastric antrum using the following formula:
Antrum area = π × r2 = π × d1/2 × d2/2 = π × d1 × d2/4
Gastric emptying rate (GER) was assessed and expressed
as the percentage reduction in antral cross-sectional area
from 15 to 90 min after meal ingestion using the follow-
ing formula:
Table 1: The gastric antral area
Antrum Area Saline Oxytocin Atosiban
Cm2 Cm2 Cm2
15 min 704 (606 – 796) 622 (420 – 872) 512 (389 – 748)*
90 min 293 (222 – 505) 349 (141 – 522) 315 (230 – 520)
The area between saline and atosiban differed at 15 min, * = p < 0.05. Median, q1-q3; n = 10. Wilcoxon signed rank test.BMC Gastroenterology 2006, 6:11 http://www.biomedcentral.com/1471-230X/6/11
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GER = [1 – (Antrum area 90 min/Antrum area 15 min)] ×
100. This method has been evaluated in comparison to
scintigraphic measurements of gastric emptying, and
ultrasonographic gastric emptying rate has been shown to
strongly correlate to scintigraphic half-time values [10].
Experimental design
The subjects were examined between 8 and 11 AM, after
an 8-hour fast. Smoking was prohibited for 8 h before and
during the test. Each subject was checked for normal fast-
ing blood glucose concentration on the day of the exami-
nation. If the subjects on the study day reported
symptoms from the gastrointestinal tract (i.e. diarrhoea or
constipation), the examination was postponed. The test
meal had to be ingested within 5 minutes. Gastric empty-
ing was examined ultrasonographically after 15 and 90
minutes and at the same time, as well as prior the study,
the subjects had to complete a questionnaire about their
grade of hunger and/or feeling of satiety using visual sati-
ety scores with a scoring graded from 0, from extreme
hunger, to 20, for extreme satiety. The drug infusion was
started at the same time as the start of the meal ingestion,
and lasted throughout the experiment. With at least two
days in between all subjects underwent the examination
three times at different occasions given either infusion of
the drugs previously described. The sequence of experi-
ments was randomly assigned and the ultrasound exami-
nations performed by the same radiologist, who was
blinded with regard to the drugs given to the subjects.
Statistical analyses
Values are given as median and interquartile ranges
(IQR). The areas under the curves (AUCs) for each subject
were determined for the satiety scores (Graph Pad PRISM,
San Diego). The areas, GER, the satiety AUCs and the sati-
ety scores between saline and oxytocin respective atosiban
were compared using Wilcoxon signed rank test. P < 0.05
was considered statistically significant.
Results
Gastric emptying rate (GER)
The gastric antral area was reduced at 15 min in the group
receiving atosiban compared to saline (Table 1). Infusion
of saline led to a GER of 57 (44–63) %. During infusion
of the oxytocin receptor antagonist atosiban, the GER was
significantly reduced by 37 % to 36 (22–48) % (Fig 1).
The individual change in GER is shown in Figure 2. In
contrast, infusion of oxytocin led to a GER of 44 (39–62)
% which did not differ from saline (p = 0.610). Five indi-
viduals had a reduced, and 5 had an increased GER during
oxytocin infusion compared to saline.
Satiety
The AUC at 0–15 min and 0–90 min for satiety was not
significantly prolonged after receiving atosiban or oxy-
tocin compared to saline (Table 2). Neither were there any
significant differences between the satiety scores (Figure
3).
Discussion
This study showed a decreased gastric emptying rate after
blockage of the oxytocin receptors, whereas a pharmaco-
logical dosage of oxytocin did not affect the emptying rate.
We have earlier described how oxytocin is released in
response to a fatty meal in healthy women (1.0 ± 0.17
basally compared to 1.3 ± 0.26 pmol/l postprandially, p =
0.02) [1] and in patients with diabetes mellitus of both
sexes (208.1 ± 148.7 basally compared to 250.6 ± 166.9
pg/ml postprandially, p = 0.02) [Ohlsson et al, unpub-
lished observation], why it can be assumed that oxytocin
release is induced also after intake of the present meal. By
The individual gastric emptying rate (GER) during saline and  atosiban Figure 2
The individual gastric emptying rate (GER) during saline and 
atosiban. All but two of subjects had a decreased GER during 
atosiban administration.
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The gastric emptying rate (GER) was decreased in the group  receiving atosiban compared to the group receiving saline Figure 1
The gastric emptying rate (GER) was decreased in the group 
receiving atosiban compared to the group receiving saline. 
Wilcoxon signed rank test.
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inhibition of the binding of endogenous oxytocin to the
oxytocin receptors, the gastric emptying was delayed. As
the antral area was reduced at 15 min after atosiban, one
may speculate if retention of food in the proximal ventri-
cle may be partly responsible for the delayed emptying
rate, or a rapid initial emptying has occurred. The trans-
port of food from the proximal to the distal part of the
ventricle may be as important as the transport from the
antrum to the duodenum.
The neurophyseal hormones vasopressin and oxytocin are
cyclic nonapetides whose actions are mediated by stimu-
lation of specific G protein-coupled receptors currently
classified into V1 – vascular, V2 – renal and V3 – pituitary
vasopressin receptors and oxytocin receptors. Vasopressin
is the ligand having the highest affinity for the human V-
receptors, while oxytocin is the ligand with the highest
affinity for the oxytocin receptor. However, there is cross-
reactivity of the ligands to the receptors [11].
Atosiban is an analogue of oxytocin and has been ration-
ally designed to compete with endogenous oxytocin at
myometrial and decidual oxytocin receptors. Clinical
studies have revealed that atosiban is an effective and safe
tocolytic agent [12]. However, atosiban has an equal, if
not a greater, affinity for vasopressin receptors compared
with oxytocin receptors due to their close chemical
homology [7,8]. Furthermore, an additional intracellular
process may be attributed as atosiban has been shown to
dose-dependently inhibit oxytocin-induced second mes-
sengers [13,14]. This intracellular inhibition was stronger
against oxytocin than against vasopressin [15]. No pure
oxytocin receptor antagonist is available for clinical use,
and may be very difficult to develop.
Thus, we cannot know that the inhibitory effect of atosi-
ban on the gastric emptying is mediated exclusively
through oxytocin receptors. The effects observed due to
inhibition of endogenous oxytocin to oxyocin/vaso-
pressin receptors by atosiban may theoretically be due to
inhibition of endogenous vasopressin as well. However,
the effect of vasopressin on the GI tract is only rudimen-
tary examined, and we do not know if vasopressin is
released in response to a meal. The expression of vaso-
pressin receptors in the human GI tract has never been
studied to our knowledge, although studies have shown
the expression of vasopressin in gastric and duodenal cells
in the rat [16]. Vasopressin has been shown to influence
gastric motility in women [17]. One study [18] has shown
that vasopressin increases the colonic peristalsis in a way
similar to oxytocin [5]. The precise mechanism for the
action of atosiban in the GI tract has thus to be further
evaluated. It remains to settle to what extent oxytocin, and
to what extent vasopressin is involved in the regulation of
GI motility. In the obstetrics, where atosiban has been
developed as a tocolytic drug, this is not a problem as an
increased expression of oxytocin receptors but not vaso-
pressin receptors is found in the uterus during labour
[19].
Earlier studies in man have shown that oxytocin improves
gastric emptying [3,4]. However, oxytocin in our present
study failed to improve the emptying rate. This may
depend on the dosage of the peptide. The reason for
choosing this dosage was that this was the highest dosage
recommended by the drug company. Further, this dosage
has in an earlier dose-response study been shown to stim-
ulate colonic peristalsis [5]. It is a well-known phenome-
non that stimulation of a receptor in increasing dosages
No significant difference could be shown between the rela- tive satiety scores in healthy subjects after receiving oxytocin  and atosiban compared to saline, n = 10 Figure 3
No significant difference could be shown between the rela-
tive satiety scores in healthy subjects after receiving oxytocin 
and atosiban compared to saline, n = 10. Satiety score at the 
start of the experiment was set to 0. Wilcoxon signed rank 
test.
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Table 2: Satiation scores areas in healthy subjects
Area under the curve Saline Oxytocin Atosiban
cm × min cm × min cm × min
0 – 15 min 934 (736 – 1077) 924 (665 – 1022) 1025 (706 – 1189)
0 – 90 min 118 (90 – 152) 132 (76 – 152) 114 (84 – 152)
Satiation scores areas after receiving oxytocin and atosiban did not differ significantly from saline. Median, q1-q3; n = 10. Wilcoxon signed rank test.BMC Gastroenterology 2006, 6:11 http://www.biomedcentral.com/1471-230X/6/11
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may show a bell-shaped response [20,21], explaining
divergent effects of the same dosage depending on the
receptor affinity and/or amount at different sites of the GI
tract. Oxytocin may be of importance for the gastric emp-
tying during physiological conditions, although not our
actual pharmacological dosage was. The test meal per se
may have given a high enough endogenous oxytocin
secretion. Stimulation by our modest pharmacological
dosage of oxytocin during these circumstances may be of
no further benefit. Furthermore, the oxytocin receptor
mRNA found [2] may be involved in regulation of slow
waves, mixing movements and liquid emptying, effects
not possible to be detected by this method. The actual
method measured the gastric volume at two different time
points, and thereby could the gastric emptying rate be cal-
culated, but the gastric emptying process is not studied in
detail.
Petring [3] used dosages of 0.33 U oxytocin/min in alto-
gether 30 min, which should be compared to our dosage
of 40 mU oxytocin/min. The dosages used by Hashmonai
et al [4] to treat gastric atony were in the range of 20–80
mU/min, but lasted for three days. Although oxytocin has
an effect on dysmotility in these dosages on an empty
stomach, it is not clear that it might have any effects with
the same dosages in healthy volunteers after a meal.
In contrast to the above findings in human, the motility
in the rat stomach was inhibited by oxytocin [21,22]. We
haven't been able to identify any oxytocin receptors in the
rat GI tract (Ohlsson et al, unpublished observation). This
might explain why the effects evoked by oxytocin on gas-
tric and intestinal motility in rat are mediated by release
of cholcystokinin (CCK) (which inhibits gastric empty-
ing) and CCK receptors, and differ from oxytocin effects
evoked in human [21,22].
This study has some limitations. Only one dosage of oxy-
tocin was examined. This was a pilote trial, and it is diffi-
cult to examine the same subjects more than three times.
Before planning next study, the optimal dosage of oxy-
tocin for gastric motility must be titrated. So far, the inter-
est for vasopressin has been modest, but after the present
results also vasopressin will be further evaluated. How-
ever, before examining the effect of vasopressin on human
GI tract, we have to examine if the receptors are present,
and if there is a postprandial vasopressin response.
Conclusion
Blockage of oxytocin and vasopressin receptors in man
inhibited the gastric emptying. It remains to determine
whether it is oxytocin or vasopressin, or both, that is most
important for gastric motility. However, one or both of
these peptides seem to be regulators of gastrointestinal
physiology in healthy subjects. The level of action needs
to be determined. Further, the role of these peptides in the
pathophysiology of gastro paresis remains to be settled.
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